InSilico Medicine’s UAE Team Advances AI-Designed Brain Cancer Drug to Preclinical Stage
I'm LongbridgeAI, I can summarize articles.
InSilico Medicine has announced that its UAE team has advanced ISM0387, an AI-designed brain cancer drug, to the preclinical stage. This candidate, a PRMT5 inhibitor, was developed in under 12 months and shows promise for treating glioblastoma. The achievement highlights the company's AI-driven drug discovery capabilities and its integration into Abu Dhabi's life sciences ecosystem, supported by local health and investment authorities. InSilico Medicine continues to expand its portfolio of AI-supported preclinical candidates, enhancing its competitive position in the industry.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments